Farrow Financial Inc. Raises Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Farrow Financial Inc. raised its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 1.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 20,097 shares of the company’s stock after purchasing an additional 270 shares during the period. Farrow Financial Inc.’s holdings in CRISPR Therapeutics were worth $777,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. ARK Investment Management LLC lifted its holdings in CRISPR Therapeutics by 19.7% during the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after purchasing an additional 1,474,439 shares in the last quarter. State Street Corp lifted its holdings in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares in the last quarter. FMR LLC lifted its holdings in CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after purchasing an additional 23,075 shares in the last quarter. Geode Capital Management LLC lifted its holdings in CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares in the last quarter. Finally, Baker BROS. Advisors LP lifted its holdings in shares of CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after buying an additional 743,075 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity

In related news, Director John Greene bought 7,000 shares of the stock in a transaction dated Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the purchase, the director now owns 7,000 shares of the company’s stock, valued at $313,950. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on CRSP. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Evercore ISI raised shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and boosted their target price for the stock from $60.00 to $99.00 in a report on Friday, February 14th. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday, February 13th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a report on Wednesday, February 12th. Finally, The Goldman Sachs Group lowered their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $73.11.

CRISPR Therapeutics Stock Up 5.1 %

CRSP stock opened at $45.53 on Friday. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $81.73. The stock has a market capitalization of $3.91 billion, a price-to-earnings ratio of -10.42 and a beta of 1.77. The firm’s fifty day simple moving average is $42.79 and its two-hundred day simple moving average is $45.77.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.